| 000 | 05058nam a2201225Ia 4500 | ||
|---|---|---|---|
| 000 | 02886ntm a2200205 i 4500 | ||
| 001 | 92069 | ||
| 003 | 0 | ||
| 005 | 20250920173404.0 | ||
| 008 | 250321n 000 0 eng d | ||
| 010 |
_z _z _o _a _b |
||
| 015 |
_22 _a |
||
| 016 |
_2 _2 _a _z |
||
| 020 |
_e _e _a _b _z _c _q _x |
||
| 022 |
_y _y _l _a2 |
||
| 024 |
_2 _2 _d _c _a _q |
||
| 028 |
_a _a _b |
||
| 029 |
_a _a _b |
||
| 032 |
_a _a _b |
||
| 035 |
_a _a _b _z _c _q |
||
| 037 |
_n _n _c _a _b |
||
| 040 |
_e _erda _a _d _b _c |
||
| 041 |
_e _e _a _b _g _h _r |
||
| 043 |
_a _a _b |
||
| 045 |
_b _b _a |
||
| 050 |
_a _a _d _b2 _c0 |
||
| 051 |
_c _c _a _b |
||
| 055 |
_a _a _b |
||
| 060 |
_a _a _b |
||
| 070 |
_a _a _b |
||
| 072 |
_2 _2 _d _a _x |
||
| 082 |
_a _a _d _b2 _c |
||
| 084 |
_2 _2 _a |
||
| 086 |
_2 _2 _a |
||
| 090 |
_a _a _m _b _q |
||
| 092 |
_f _f _a _b |
||
| 096 |
_a _a _b |
||
| 097 |
_a _a _b |
||
| 100 |
_e _e _aBarba, Joana Rose D., Barlaan Kaye Marie T., Borromeo, Beatriz C., Fulgar, Kyla Nicole S., Reyes, Cyrine Joy F., Rodriguez, Nicole, Ventenilla, Chrish Andrea H. _d _b4 _u _c0 _q16 |
||
| 110 |
_e _e _a _d _b _n _c _k |
||
| 111 |
_a _a _d _b _n _c |
||
| 130 |
_s _s _a _p _f _l _k |
||
| 210 |
_a _a _b |
||
| 222 |
_a _a _b |
||
| 240 |
_s _s _a _m _g _n _f _l _o _p _k |
||
| 245 | 0 |
_a _aA five-year strategic financial plan for Sun Pharmaceutical Philippines, Inc / _d _b _n _cBarba, Joana Rose D., Barlaan Kaye Marie T., Borromeo, Beatriz C., Fulgar, Kyla Nicole S., Reyes, Cyrine Joy F., Rodriguez, Nicole, Ventenilla, Chrish Andrea H. _h6 _p |
|
| 246 |
_a _a _b _n _i _f6 _p |
||
| 249 |
_i _i _a |
||
| 250 |
_6 _6 _a _b |
||
| 260 |
_e _e _a _b _f _c _g |
||
| 264 |
_3 _3 _a _d _b _cDecember 2023.46 |
||
| 300 |
_e _e _c28 cm. _a205 pages _b |
||
| 310 |
_a _a _b |
||
| 321 |
_a _a _b |
||
| 336 |
_b _atext _2rdacontent |
||
| 337 |
_3 _30 _b _aunmediated _2rdamedia |
||
| 338 |
_3 _30 _b _avolume _2rdacarrier |
||
| 340 |
_2 _20 _g _n |
||
| 344 |
_2 _2 _a0 _b |
||
| 347 |
_2 _2 _a0 |
||
| 362 |
_a _a _b |
||
| 385 |
_m _m _a2 |
||
| 410 |
_t _t _b _a _v |
||
| 440 |
_p _p _a _x _v |
||
| 490 |
_a _a _x _v |
||
| 500 |
_a _aFinancial Plan: (BSBA major in Financial Management) - Pamantasan ng Lungsod ng Maynila, 2023. _d _b _c56 |
||
| 504 |
_a _a _x |
||
| 505 |
_a _a _b _t _g _r |
||
| 506 |
_a _a5 |
||
| 510 |
_a _a _x |
||
| 520 |
_b _b _c _aExecutive Summary Sun Pharmaceutical Industries, Ltd., India's largest pharmaceutical company and the world's fourth-largest generic pharmaceutical company, is a leading global provider of high-quality products. Established in 2011, Sun Pharma Philippines, Inc. is part of the emerging Asia branches of Sun Pharmaceutical Industries, Ltd. and focuses on distributing finished goods from its manufacturing facilities in Malaysia, Thailand, and India. The company uses an inside marketing strategy, targeting doctors for product promotion and employing wholesalers for distribution. Sun Pharma specializes in therapeutic categories like mental health, oncology, ophthalmology, dermatology, and gastroenterology, with a longer shelf life compared to competitors. The company is also committed to social responsibility, participating in donation drives for key healthcare institutions. The company's financial statements from 2019 to 2023 reveal inconsistent net profit despite consistent revenue growth. This highlights a persistent imbalance between expenses and revenue, where expenses consistently outpace income, negatively impacting the company's ability to meet its liabilities and maintain financial stability. This situation demands immediate attention and the implementation of strategic financial measures to address these ongoing challenges for the company. The proponents aim to improve Sun Pharma Philippines, Inc.'s inconsistent net profit despite consistent revenue growth by implementing a strategic financial plan. The plan analyzes the company's financial situation, identifying areas for improvement and suggesting alternative actions to minimize profitability challenges. This strategy approach intends to ensure financially stable and efficient operational future endeavors for Sun Pharma Philippines, Inc. _u |
||
| 521 |
_a _a _b |
||
| 533 |
_e _e _a _d _b _n _c |
||
| 540 |
_c _c _a5 |
||
| 542 |
_g _g _f |
||
| 546 |
_a _a _b |
||
| 583 |
_5 _5 _k _c _a _b |
||
| 590 |
_a _a _b |
||
| 600 |
_b _b _v _t _c2 _q _a _x0 _z _d _y |
||
| 610 |
_b _b _v _t2 _x _a _k0 _p _z _d6 _y |
||
| 611 |
_a _a _d _n2 _c0 _v |
||
| 630 |
_x _x _a _d _p20 _v |
||
| 648 |
_2 _2 _a |
||
| 650 |
_x _x _a _d _b _z _y20 _v |
||
| 651 |
_x _x _a _y20 _v _z |
||
| 655 |
_0 _0 _a _y2 _z |
||
| 700 |
_i _i _t _c _b _s1 _q _f _k40 _p _d _e _a _l _n6 |
||
| 710 |
_b _b _t _c _e _f _k40 _p _d5 _l _n6 _a |
||
| 711 |
_a _a _d _b _n _t _c |
||
| 730 |
_s _s _a _d _n _p _f _l _k |
||
| 740 |
_e _e _a _d _b _n _c6 |
||
| 753 |
_c _c _a |
||
| 767 |
_t _t _w |
||
| 770 |
_t _t _w _x |
||
| 773 |
_a _a _d _g _m _t _b _v _i _p |
||
| 775 |
_t _t _w _x |
||
| 776 |
_s _s _a _d _b _z _i _t _x _h _c _w |
||
| 780 |
_x _x _a _g _t _w |
||
| 785 |
_t _t _w _a _x |
||
| 787 |
_x _x _d _g _i _t _w |
||
| 800 |
_a _a _d _l _f _t0 _q _v |
||
| 810 |
_a _a _b _f _t _q _v |
||
| 830 |
_x _x _a _p _n _l0 _v |
||
| 942 |
_a _alcc _cBK |
||
| 999 |
_c24114 _d24114 |
||